Carsten Nieder1,2, Laurie E Gaspar3, Dirk De Ruysscher4, Matthias Guckenberger5, Minesh P Mehta6, Chad G Rusthoven3, Arjun Sahgal7, Eleni Gkika8. 1. Department of Oncology and Palliative Medicine, Nordland Hospital, 8092, Bodø, Norway. carsten.nieder@nlsh.no. 2. Department of Clinical Medicine, Faculty of Health Sciences, UiT-The Arctic University of Norway, Tromsø, Norway. carsten.nieder@nlsh.no. 3. Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, CO, USA. 4. Department of Radiation Oncology, MAASTRO Clinic, Maastricht, The Netherlands. 5. Department of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland. 6. Department of Radiation Oncology, Miami Cancer Institute, Miami, FL, USA. 7. Department of Radiation Oncology, Sunnybrook Health Sciences Centre and University of Toronto, Toronto, Canada. 8. Department of Radiation Oncology, University Hospital Freiburg, Freiburg, Germany.
Abstract
BACKGROUND: Improved survival of patients with spinal bone metastases has resulted in an increased number of referrals for retreatment and repeat reirradiation. METHODS: A consortium of expert radiation oncologists (RO) has been established with the aim of providing treatment recommendations for challenging clinical scenarios for which there are no established guidelines. In this case, a patient developed local progression of a T5 vertebral lesion after two prior courses of palliative radiotherapy (time interval >12 months, assumed cumulative biologically equivalent dose in 2‑Gy fractions [EQD2] for spinal cord [alpha/beta 2 Gy] 75 Gy). Expert recommendations were tabulated with the aim of providing guidance. RESULTS: Five of seven RO would offer a third course of radiotherapy, preferably with advanced techniques such as stereotactic radiotherapy. However, the dose-fractionation concepts were heterogeneous (3-20 fractions) and sometimes adjusted to different options for systemic treatment. All five RO would compromise target volume coverage to reduce the dose to the spinal cord. Definition of the spinal cord planning-organ-at-risk volume was heterogeneous. All five RO limited the EQD2 for spinal cord. Two were willing to accept more than 12.5 Gy and the highest EQD2 was 19 Gy. CONCLUSIONS: The increasing body of literature about bone metastases and spinal cord reirradiation has encouraged some expert RO to offer palliative reirradiation with cumulative cord doses above 75 Gy EQD2; however, no consensus was achieved. Strategies for harmonization of clinical practice and development of evidence-based dose constraints are discussed.
BACKGROUND: Improved survival of patients with spinal bone metastases has resulted in an increased number of referrals for retreatment and repeat reirradiation. METHODS: A consortium of expert radiation oncologists (RO) has been established with the aim of providing treatment recommendations for challenging clinical scenarios for which there are no established guidelines. In this case, a patient developed local progression of a T5 vertebral lesion after two prior courses of palliative radiotherapy (time interval >12 months, assumed cumulative biologically equivalent dose in 2‑Gy fractions [EQD2] for spinal cord [alpha/beta 2 Gy] 75 Gy). Expert recommendations were tabulated with the aim of providing guidance. RESULTS: Five of seven RO would offer a third course of radiotherapy, preferably with advanced techniques such as stereotactic radiotherapy. However, the dose-fractionation concepts were heterogeneous (3-20 fractions) and sometimes adjusted to different options for systemic treatment. All five RO would compromise target volume coverage to reduce the dose to the spinal cord. Definition of the spinal cord planning-organ-at-risk volume was heterogeneous. All five RO limited the EQD2 for spinal cord. Two were willing to accept more than 12.5 Gy and the highest EQD2 was 19 Gy. CONCLUSIONS: The increasing body of literature about bone metastases and spinal cord reirradiation has encouraged some expert RO to offer palliative reirradiation with cumulative cord doses above 75 Gy EQD2; however, no consensus was achieved. Strategies for harmonization of clinical practice and development of evidence-based dose constraints are discussed.
Entities:
Keywords:
Bone metastases; In-field relapse; Local control; Palliative radiotherapy; Radiation myelopathy
Authors: Edward Chow; Keyue Ding; Wendy R Parulekar; Rebecca K S Wong; Yvette M van der Linden; Daniel Roos; William F Hartsell; Peter Hoskin; Jackson S Y Wu; Abdenour Nabid; Jan Willem Leer; Ernest Vonk; Scott Babington; William F Demas; Carolyn F Wilson; Michael Brundage; Liting Zhu; Ralph M Meyer Journal: Radiother Oncol Date: 2015-10-26 Impact factor: 6.280
Authors: Arya Amini; Basel Altoos; Maria T Bourlon; Edward Bedrick; Shilpa Bhatia; Elizabeth R Kessler; Thomas W Flaig; Christine M Fisher; Brian D Kavanagh; Elaine T Lam; Sana D Karam Journal: Pract Radiat Oncol Date: 2015-06-30
Authors: Isabelle Thibault; Ameen Al-Omair; Giuseppina Laura Masucci; Laurence Masson-Côté; Fiona Lochray; Renée Korol; Lu Cheng; Wei Xu; Albert Yee; Michael G Fehlings; Georg A Bjarnason; Arjun Sahgal Journal: J Neurosurg Spine Date: 2014-08-29
Authors: Christina Leitzen; Timo Wilhelm-Buchstab; Sabina Stumpf; Martina Heimann; David Koch; Christopher Schmeel; Birgit Simon; Susanne Vornholt; Stephan Garbe; Fred Röhner; Felix Schoroth; Hans Heinz Schild; Heinrich Schüller; Thomas Müdder Journal: Strahlenther Onkol Date: 2019-03-26 Impact factor: 3.621
Authors: Olaf Wittenstein; Patrick Hiepe; Lars Henrik Sowa; Elias Karsten; Iris Fandrich; Juergen Dunst Journal: Strahlenther Onkol Date: 2019-04-29 Impact factor: 3.621